Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (noting a discrepancy with the metadata request for "Avalo Therapeutics") on June 4, 2021. The filing reports the entry into a material definitive agreement involving a venture debt financing arrangement.
Key Financial Metrics and Agreement Terms
- Total Facility Size: $35.0 million.
- Initial Funding: $20.0 million funded on the Closing Date (June 4, 2021).
- Contingent Funding: Remaining $15.0 million fundable upon achieving predetermined milestones.
- Interest Rate: 6.25% plus the prime rate (subject to a 3.25% floor).
- Maturity: Advances mature 42 months from the first day of the month following funding (Initial tranche matures January 1, 2025).
- Repayment Terms: Interest-only payments through January 1, 2023 (potentially extendable to July 1, 2023). Monthly principal and interest amortization begins thereafter.
- Prepayment Penalties: 3% if prepaid on or before the amortization date; 2% if prepaid within 12 months after; 1% thereafter.
- Final Payment: 3% of each loan due at maturity or prepayment.
- Warrant Coverage: 8 warrants issued to purchase 403,844 shares of common stock at an exercise price of $2.60 per share, exercisable for 10 years.
- Collateral: Lien on substantially all assets, excluding Intellectual Property and Excluded Collateral.
Material Changes and Purpose
The primary material change is the creation of a new direct financial obligation. The proceeds are designated for general corporate purposes, specifically to support the ongoing clinical development of key investigational product candidates and to cover general and administrative expenses.
Outlook, Risks, and Contingencies
- Covenants: The agreement includes customary covenants limiting dividends, additional indebtedness, investments, distributions, and mergers/acquisitions.
- Events of Default: Include failure to make payments, breach of covenants, material adverse change, insolvency, or material defaults on other obligations exceeding $200,000.
- Default Consequences: Lenders may accelerate loan amounts and enforce liens. Default interest accrues at an additional 5% per annum.
- Financial Reporting: The company must adhere to financial reporting covenants.
Investor Verification Checklist
- Verify the specific "predetermined milestones" required to unlock the remaining $15.0 million tranche.
- Confirm the current prime rate to calculate the exact effective interest rate.
- Review the upcoming Form 10-Q for the full text of the Loan Agreement and detailed warrant terms.
- Assess the impact of the 3% final payment and potential prepayment penalties on future liquidity.
- Monitor compliance with the financial reporting covenants and restrictions on additional indebtedness.